印尼主權財富基金據報洽商在Grab(GRAB.US)併購GoTo後 取得合併後公司權益
《彭博》引述消息報道,印尼主權財富基金Danantara Indonesia正與召車及電商平臺GoTo初步談判,尋求在新加坡召車及外賣平臺Grab(GRAB.US)對GoTo完成潛在收購後,於合併後的實體中取得少數股權。
上月市傳Grab計劃第二季達成併購交易,對GoTo估值約70億美元。《彭博》報道指,雙方在交易結構上已取得進展,但由於潛在監管要求,談判進度有所放緩。印尼反壟斷監管機構上月啓動調查,目前Grab及GoTo尚未正式確認合併談判。
Danantara Indonesia今年2月成立,該基金將持有國企股權,並計劃仿效新加坡投資機構淡馬錫的運作模式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.